Carfilzomib

Therapeutic

Indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. 

Structural features

SMILES

CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

Sequence

XXLFX

Molar mass

719.924 g/mol

Constitutional members:

5

Natural amino acids

2

D-Amino acids

0

N-terminus

2-morpholinacetyl

C-terminus

2-amino-4-methyl-1-[2-methyloxiran-2-yl]pentan-1-one

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

no

Route of administration

IV

Terminal half-life

≤1 hour

Protein binding

0.97

Absorption and Bioavailability

-

References